Log in

NASDAQ:IMACIMAC Stock Price, Forecast & News

-0.03 (-1.95 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $1.51
50-Day Range
MA: $1.59
52-Week Range
Now: $1.51
Volume36,742 shs
Average Volume729,877 shs
Market Capitalization$15.11 million
P/E RatioN/A
Dividend YieldN/A
IMAC Holdings, Inc. operates a chain of integrated medicine and chiropractic regeneration centers. The company's outpatient clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. As of September 17, 2018, it had 11 clinics, including 6 owned and 5 managed clinics in Kentucky, Missouri, and Tennessee, the United States. The company was founded in 2000 and is based in Brentwood, Tennessee.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Current SymbolNASDAQ:IMAC



Sales & Book Value

Annual Sales$15.13 million
Book Value$0.93 per share


Net Income$-6,500,000.00


Market Cap$15.11 million
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive IMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

IMAC (NASDAQ:IMAC) Frequently Asked Questions

How has IMAC's stock been impacted by COVID-19 (Coronavirus)?

IMAC's stock was trading at $0.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMAC stock has increased by 84.1% and is now trading at $1.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IMAC?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMAC.

When is IMAC's next earnings date?

IMAC is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for IMAC.

How were IMAC's earnings last quarter?

IMAC Holdings Inc (NASDAQ:IMAC) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The firm had revenue of $3.32 million for the quarter, compared to analyst estimates of $5.72 million. IMAC had a negative return on equity of 80.08% and a negative net margin of 41.20%. View IMAC's earnings history.

What price target have analysts set for IMAC?

2 brokerages have issued 12-month target prices for IMAC's shares. Their forecasts range from $4.50 to $4.50. On average, they expect IMAC's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 198.0% from the stock's current price. View analysts' price targets for IMAC.

Has IMAC been receiving favorable news coverage?

News headlines about IMAC stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMAC earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutIMAC.

Are investors shorting IMAC?

IMAC saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 46,800 shares, a drop of 45.8% from the April 30th total of 86,400 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.9% of the shares of the stock are sold short. View IMAC's Current Options Chain.

Who are some of IMAC's key competitors?

What other stocks do shareholders of IMAC own?

Who are IMAC's key executives?

IMAC's management team includes the following people:
  • Mr. Jeffrey S. Ervin M.B.A., CEO & Director (Age 41)
  • Mr. D. Anthony Bond CPA, Chief Financial Officer (Age 57)
  • Dr. Matthew C. Wallis, COO & Director (Age 45)
  • Mr. Jeff Ervin, Chief Exec. Officer
  • Dr. Ian A. White Ph.D., Chief Scientific Officer (Age 44)

When did IMAC IPO?

(IMAC) raised $4 million in an initial public offering on the week of February 11th 2019. The company issued 900,000 shares at a price of $5.00 per share. Dawson James Securities and Cuttone served as the underwriters for the IPO.

What is IMAC's stock symbol?

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

How do I buy shares of IMAC?

Shares of IMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMAC's stock price today?

One share of IMAC stock can currently be purchased for approximately $1.51.

How big of a company is IMAC?

IMAC has a market capitalization of $15.11 million and generates $15.13 million in revenue each year. The company earns $-6,500,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

What is IMAC's official website?

The official website for IMAC is www.imacregeneration.com.

How can I contact IMAC?

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company can be reached via phone at 844-266-4622 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.